Jesse D. Malkin
RAND Corporation
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jesse D. Malkin.
Obstetrics & Gynecology | 2000
Jesse D. Malkin; Steven Garber; Michael S. Broder; Emmett B. Keeler
Objective To assess additional risk of newborn death owing to early discharge. Methods This was a historical cohort study using Washington State linked birth certificates, death certificates, and hospital discharge records that covered 47,879 live births in 1989 and 1990. Logistic regression was used to assess risk of death within the first year of life after early discharge (less than 30 hours after birth) compared with later discharge (30–78 hours after birth). Results Newborns discharged early were more likely to die within 28 days of birth (odds ratio [OR] 3.65; 95% confidence interval [CI] 1.56, 8.54), between 29 days and 1 year (OR 1.61; 95% CI 1.10, 2.36), and any time within the first year (OR 1.84; 95% CI, 1.31, 2.60) of life than newborns sent home later. Newborns discharged early also were more likely to die of heart-related problems (OR 3.72; CI 1.25, 11.04) and infections (OR 4.72; CI 1.13, 19.67) within 1 year of birth than newborns discharged later. Conclusion Newborns discharged within 30 hours of birth are at increased risk of death within the first year of life.
Topics in Economic Analysis & Policy | 2002
Dana P. Goldman; Geoffrey F. Joyce; Jesse D. Malkin
Abstract Medicare does not have an outpatient prescription drug benefit. Recently, there has been renewed interest in adding a prescription drug benefit to the program. In this paper, we present a microsimulation model to predict drug expenditures in 2001 for a representative cohort of Medicare beneficiaries under the status quo and three different plans: (1) a catastrophic plan modeled on the Medicare Catastrophic Coverage Act (PL 100-360), which was passed in 1988 but repealed one year later after higher-income Medicare beneficiaries protested new premiums, (2) a zero-deductible plan that caps out-of-pocket expenses at
Medical Care Research and Review | 2003
Jesse D. Malkin; Michael Schoenbaum
4,000 per year, and (3) a zero-deductible plan that does not cap out-of-pocket expenses. We use data from a representative sample of Medicare Part B beneficiaries from the 1995 Medicare Current Beneficiary Survey (MCBS) Cost and Use file. Under the status quo, drug expenses average
JAMA | 1996
Emmett B. Keeler; Jesse D. Malkin; Dana P. Goldman; Joan L. Buchanan
1,459 per beneficiary, out-of-pocket costs average
Health Services Research | 2000
Jesse D. Malkin; M S Broder; Emmett B. Keeler
646, and 8.2% of the population has very high expenses (defined as more than
Health Services Research | 2010
Dana P. Goldman; Anupam B. Jena; Darius N. Lakdawalla; Jennifer Malin; Jesse D. Malkin; Eric C. Sun
2,000 out-of-pocket for drugs). Under a catastrophic plan, average annual drug expenses are
Health Services Research | 2011
Daniella Meeker; Geoffrey F. Joyce; Jesse D. Malkin; Steven M. Teutsch; Anne C. Haddix; Dana P. Goldman
1,344, out-of-pocket costs are
Pediatrics | 2003
Jesse D. Malkin; Emmett B. Keeler; Michael S. Broder; Steven Garber
645, and 6.8% of beneficiaries have very high expenses. Under a zero-deductible plan that does not cap out-of-pocket expenses average annual drug expenses are
Health Affairs | 2004
Jesse D. Malkin; Dana P. Goldman; Geoffrey F. Joyce
1,395, out-of-pocket expenses are
Archive | 2000
Jesse D. Malkin; Michael S. Broder; Emmett B. Keeler
459, and 5.3% of beneficiaries would have very high expenses. Under a zero-deductible plan that caps out-of-pocket expenses at